Press "esc" to clear
Go to Advanced Search

Showing results

110 of 1122

Article ID: 701027

Poziotinib Maintains High Response Rate Against Harmful Lung Cancer Mutation

University of Texas M. D. Anderson Cancer Center

A drug revived by researchers at The University of Texas MD Anderson Cancer Center continues to provide unprecedented response rates among stage 4 non-small cell lung cancer patients with genetic mutations that have previously defied treatment.

24-Sep-2018 4:05 PM EDT

Article ID: 701016

A Tailored Approach to Minority Tobacco Cessation Programs

University of Kansas Cancer Center

Researchers work with African American and American Indian communities to identify effective tobacco cessation strategies

24-Sep-2018 2:05 PM EDT
  • Embargo expired:
    24-Sep-2018 11:00 AM EDT

Article ID: 700943

Revisiting the Mode of Cancer Evolution

Rutgers Cancer Institute of New Jersey

Analysis by investigators at Rutgers Cancer Institute of New Jersey further examines tumor evolution through genomic data captured from thousands of cancer tumor samples using a mathematical model.

21-Sep-2018 3:30 PM EDT
  • Embargo expired:
    24-Sep-2018 9:45 AM EDT

Article ID: 700973

Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer

University of Colorado Cancer Center

Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.

24-Sep-2018 8:45 AM EDT

Article ID: 700937

September is Sickle Cell Disease Awareness Month

Rutgers Cancer Institute of New Jersey

Sickle cell disease is a common inherited blood disorder, affecting an estimated 100,000 Americans of different racial and ethnic groups. A Rutgers Cancer Institute of New Jersey expert shares more about the importance of early diagnosis and comprehensive management of this disease.

24-Sep-2018 8:00 AM EDT
  • Embargo expired:
    24-Sep-2018 5:00 AM EDT

Article ID: 700895

Cancer Cells Evade Immunotherapy by Hiding Telltale Marker, Suggesting How to Stop Relapse

Fred Hutchinson Cancer Research Center

Harnessing the immune system to treat cancer shows great promise in some patients, but for many, the response does not last long-term. In an effort to find out why, Fred Hutchinson Cancer Research Center scientists are using a new technology to look at how cancer cells change under the pressure of immunotherapy treatments.

21-Sep-2018 1:00 AM EDT

Article ID: 700961

Study seeks to improve cancer survival for Latinos, Asians and Blacks

UC Davis Comprehensive Cancer Center

UC Davis Comprehensive Cancer Center has received a $6.3 million grant from the National Cancer Institute’s (NCI) Center to Reduce Cancer Health Disparities for a 5-year study to tease out why some ethnic and racial minority groups fare worse than whites when they get cancer and to find more precise treatments to improve their chances of survival.

21-Sep-2018 5:05 PM EDT

Article ID: 700946

MD Anderson hosts Biden Cancer Community Summit

University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center today joined with more than 450 communities and institutions across the country in hosting a Biden Cancer Community Summit, organized under the charge of the Biden Cancer Initiative. The Summit aims to encourage an ongoing dialogue about opportunities to make significant advances in cancer research, prevention, diagnosis and care.

21-Sep-2018 3:05 PM EDT

Article ID: 700896

Roswell Park and URMC To Create $19 Million Research Program Focused on Flavored Tobacco

Roswell Park Comprehensive Cancer Center

The expertise of two regional research teams has earned a federal grant of nearly $20 million to create the nation’s first program dedicated to the study of flavored tobacco.

21-Sep-2018 7:40 AM EDT
Embargo will expire:
25-Sep-2018 10:00 AM EDT
Released to reporters:
20-Sep-2018 4:05 PM EDT


A reporter's PressPass is required to access this story until the embargo expires on 25-Sep-2018 10:00 AM EDT

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Showing results

110 of 1122

Chat now!